Treatment‐Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients

• DOI: 10.1111/ejh.14368
• Publication Date: 2025-02-17T08:09:01Z
• Authors: C. Kockerols; P. J. M. Valk; P. Hogenbirk; I. Geelen; N. M. A. Blijlevens; J. J. W. M. Janssen; M. Hoogendoorn; S. Kersting; S. K. Klein; L. G. M. Daenen; M. Donker; P. A. W. te Boekh...; K.‐S. G. Jie; M. Corsten; M. J. Cruijsen; H. Levenga; W. M. Smit; M.‐D. Levin; E. de Jongh; S. de Jonge; A. J. Vlot; M. F. Durian; J. J. Zwaginga; M. Mohlmann; T. J. Wustman; R. Blommers; J. J. Cornelissen; P. E. Westerweel
• Keywords: Discontinuation; Clinical endpoint; breakpoint cluster region; Cut-off

ABSTRACT Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain state remission after discontinuation, denoted as treatment‐free (TFR). Depth assessed by BCR::ABL1 digital PCR prior to discontinuation has demonstrated its significance reliable predictive parameter for TFR. A clinically applicable prediction cutoff 0.0023%IS been established and externally validated. In this study, PCR, most sensitive assay kind, was investigated TFR tool in the Netherlands, evaluated value stop below aforementioned cutoff. The primary endpoint recurrence (MolR, > 0.1%IS) at 12 months prospectively assessed. Overall, 67 discontinued set were included. overall MolR probability 50% (95% CI, 36%–62%). 38 treated more than 6 years commonly recommended desirable duration before attempt, dropped 36% 18%–50%). Patients attempting an early (treated less years) had high 76% 65%–89%). successfully used Dutch clinical practice. Our study indicates that with low result, total six or remains associated lower rate should generally be pursued. years, capable identify candidates higher success.